Regeneron Pharmaceuticals Inc (REGN)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		2.30	2.33	2.46	2.40	2.27	2.46	2.75	3.40	2.65	2.48	1.76	2.19	2.72	2.31	3.35	3.14	3.32	3.20	3.32	3.42
DSO	days	158.58	156.49	148.34	151.82	160.56	148.32	132.93	107.36	137.58	147.41	207.20	166.52	134.32	158.13	108.94	116.11	109.90	114.00	109.91	106.81

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.30
= 158.58

Regeneron Pharmaceuticals, Inc.'s days of sales outstanding (DSO) have shown a fluctuating trend over the past eight quarters. In Q4 2023, the DSO was 157.70 days, which increased compared to the previous quarter but remained below the Q4 2022 level of 159.78 days. This indicates a longer time taken by the company to collect its accounts receivable in Q4 2023.

The DSO was relatively high in the past few quarters, with Q2 2022 reaching 132.42 days and Q1 2022 at 106.99 days. The increase in DSO from Q1 2022 to Q2 2022 could possibly signify delayed or slow collection of sales revenues during that period.

The recent upward trend in DSO may imply potential challenges in managing accounts receivable and collecting payments efficiently. It is essential for Regeneron Pharmaceuticals to streamline their credit and collection processes to reduce DSO and improve cash flow in the future quarters. Further analysis and comparison with industry benchmarks may provide deeper insights into the company's effectiveness in managing its receivables.